Jefferies Global Healthcare Conference in London - EUPRAXIA PHARMACEUTICALS INC
Explicit Guidance:
- Cash Runway: Current cash and short-term investments are sufficient to fund operations through Q3 2028, covering the completion of the current trial and the initiation of Phase 3.
- Capital Requirements: An estimated incremental raise of approximately $125 million is required to complete Phase 3 trials and file an NDA.
- Trial Interim Data Timing: Interim data from Part 2 of the trial is expected in "the next several weeks," specifically targeting 60 patients at 24 weeks in December, with data for 20 patients at 52 weeks to follow.
- NDA Timing: An End-of-Phase 2 meeting is targeted for the first part of 2027, intended to drive the business forward toward an eventual launch in 2030.
Business-Segment Outlook:
- Product Launch: Anticipated launch of Eupraxia's product for Eosinophilic Esophagitis (EOE) in 2030, coinciding with the projected patient population exceeding one million in the US.
- Indication Expansion (Benign Esophageal Strictures): Management plans to initiate a Phase 2 trial for benign esophageal strictures in the US (500,000 addressable patients) within the current fiscal timeline (before Q3 2028).
- Indication Expansion (Fibrostenosynchrones): Potential expansion into fibrostenosing esophageal conditions is noted as a strategic opportunity, leveraging the same administration protocol as the EOE indication.
- Dosing Frequency: Development of a one-time, once-a-year dosing schedule; protocol amendments now track patients for two years to determine optimal timing for a potential second dose (ideally at 12 months) before symptom recurrence.
Market and Competitive Outlook:
- Target Market Size: EOE patient pool in the US grew from ~150,000 (2022) to 470,000, with an annual growth rate of ~72,000 patients, projected to exceed 1 million by 2030.
- Market Share Shift: Current biologics capture ~8% of the market; management projects this to grow to 25%, leaving ~45% of the market (currently on PPIs or non-compliant with oral steroids) as the target addressable segment.
- Competitive Advantage: Product differentiates from current approved therapies by offering a localized injection with antifibrotic effects, targeting the 60% of PPI patients who progress to fibrosis despite symptom control.
- Adoption Strategy: Designed to piggyback on existing endoscopy procedures (adding ≤10 minutes), targeting gastroenterologists who are proceduralists and already perform these visits, thereby minimizing friction with current payer workflows.
Macro / Industry Outlook:
- Regulatory Path: No longer considered an orphan indication by the FDA (status changed late 2023); safety profile is grounded against the safety expectations of the 20+ million daily users of inhaled fluticasone.
- Diagnostic Trends: IQVIA claims analysis (diagnostic code K20.0) indicates steady, conservative growth in diagnosis, suggesting under-diagnosis or improved detection is driving the 72,000 annual increase.
- Compliance Trends: High non-compliance rates (70–90%) with long-term oral steroids are identified as a structural market weakness to be exploited; intermittent steroid use is now viewed as no different than placebo.
Strategic Initiatives:
- Clinical Trial Amendment: Protocol amended to extend patient follow-up from 12 to 24 months to better characterize durability and inform second-dose timing.
- Commercial Efficiency: Leverages same GI specialists, same call points, and same submucosal injection technique for potential new indications (strictures), reducing commercialization costs.
- Data Strategy: Focus on the "trifecta" of clinical outcomes: Symptom improvement (SDI/DSQ), Histology (EOEHSS), and Endoscopic findings (EREFS) to validate consistency.
- Financial Strategy: Proceeds from future fundraising ($125M target) will fund Phase 3 completion and the Benign Esophageal Stricture Phase 2 trial execution.
Risks and Headwinds to Outlook:
- Statistical Power Concerns: Interim analysis involves small sample sizes (20–60 patients); management explicitly states that statistical significance on symptoms (DSQ) or histology is not guaranteed and any significance would be "out of the park."
- Endpoint Noise: The DSQ patient-reported outcome is described as "noisy" with high standard deviation due to imputation methods, potentially masking significance.
- Unproven Durability: While 12-month data is strong, long-term durability beyond one year and the exact requirement/timing for a second dose remain to be confirmed by the 24-month data.
- Payer/Reimbursement: While positioned as a medical benefit (procedure fee) rather than pharmacy benefit, the shift from oral steroids to a new procedural injection requires physician and payer adoption.
- Funding Dependency: Completion of Phase 3 and NDA submission is contingent on successfully raising the estimated $125 million.
Management Tone on the Future:
- Confidence: High confidence in the clinical data, citing "remarkable" efficacy (up to 80% clinical remission by six months) and "extremely well-tolerated" safety profile (zero oral candidiasis in 3,000+ injections).
- Cautious Optimism on Stats: While confident in directional trends and the biological mechanism (reversal of fibrosis), management uses hedges regarding statistical significance in the upcoming interim data due to sample size constraints.
- Urgency: Emphasizes the "very soon" timeline for the interim data and the critical need for a once-a-year dosing regimen to meet commercial and patient needs.
Miscellaneous:
- Safety Profile: No procedure-related complications (perforation, abscess, hematoma, bleeding) observed in over 3,000 individual injections; no adrenal or cortisol suppression observed.
- Mechanism of Action: Targets upstream inflammatory cytokines and demonstrates direct antifibrotic effects, distinguishing it from therapies that only reduce eosinophil counts (which have shown poor correlation with clinical symptom relief).
- Communication: Company will go "quiet" following the presentation until after the interim data release; detailed commercial information available via website webinar.
- Company
- EUPRAXIA PHARMACEUTICALS INC
- Keywords
- EUPRAXIA PHARMACEUTICALS INC